Past year
All results
- All results
- Verbatim
Aug 22, 2023 · On June 5, 2023, the Company was awarded a $750,000 research and development grant from the Army Medical Research and Material Command for a pre-clinical study ...
Feb 12, 2024 · For the Traumatic Brain Injury program (mTBI), Alpha Cognition was awarded a grant from the Army Medical Research and Material Command (AMRMC) for a pre ...
Feb 12, 2024 · Upon FDA approval, the company plans to launch commercially into the Long Term Care (LTC) market segment. The LTC market covers more than 35% of the overall ...
Apr 3, 2024 · The new formulation has demonstrated active drug release in <30 seconds, 90% bioavailability, and a safe and well tolerated compound. Financial Highlights for ...
Nov 28, 2023 · On June 5, 2023, the Company was awarded a $750,000 research and development grant from the Army Medical Research and Material Command for a pre-clinical study ...
7 days ago · The Company completed its PPM financing of $8.45 million (all amounts in USD), which included fully subscribed 30% overallotment, with the final closing of $3.7 ...
Apr 3, 2024 · The filing was based on novel and unexpected findings in the clinical trial work the company completed and further demonstrates the uniqueness of ALPHA-1062.
Jan 22, 2024 · need for additional financing to maintain operations; risks posed by the economic and political environments in which the Company operates and intends to ...
Missing: funding | Show results with:funding
Dec 8, 2023 · The US FDA has accepted Alpha Cognition's new drug application (NDA) for ALPHA-1062 to treat mild-to-moderate Alzheimer's disease.
6 days ago · Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative disorders, has shared its financial results and updated it for the first ...
Missing: funding | Show results with:funding